Shots:
- Lynk Pharmaceuticals has entered into an exclusive development & licensing agreement with Formation Bio, granting the latter worldwide rights to LNK01006 (excl. Greater China), a highly selective TYK2 inhibitor
- LNK01006 will be developed by Formation’s new subsidiary, Bleecker Bio, following recent US FDA IND clearance, with a P-I trial planned to start in the H1’26
- As per the deal, Lynk Pharmaceuticals will receive an upfront payment, a minority equity stake in Bleecker Bio, & ~$605M in development, regulatory, & commercial milestones, along with tiered royalties
Ref: PRnewswire | Image: Lynk & Formation |Press Release
Related News: Novartis and Relation Therapeutics Ink ~$1.75B Atopic Disease Target-Discovery Alliance
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
